Exploring the role of neutrophil-to-lymphocyte ratio and blood chemistry in head and neck adenoid cystic carcinomas treated with carbon ion radiotherapy

Barcellini, Amelia; Fontana, Giulia; Filippini, Daria Maria; Ronchi, Sara; Bonora, Maria; Vischioni, Barbara; Ingargiola, Rossana; Camarda, Anna Maria; Loap, Pierre; Facchinetti, Nadia; Licitra, Lisa; Baroni, Guido; Orlandi, Ester

doi:10.1016/j.radonc.2022.10.027

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In CNAO's clinical practice, CIRT is delivered in two volume doses: the high-risk clinical target volume (CTV) includes a macroscopic tumour with a margin of 3-5 mm, whereas the low-risk CTV encompasses high-risk CTV plus 2-5 mm of safety margins, the perineural or compartmental spread of the disease. In a subset of this patient cohort, we found that the baseline neutrophil-to-lymphocyte ratio and haemoglobin values appeared to be independent prognostic predictors for clinical outcomes, suggesting that CIRT may dictate the immune response and potentially the outcome [26]. Using the modified microdosimetric kinetic model, we recently recalculated local effect model (LEM) plans for ACC treatment to assess the different impacts on outcome and toxicity [27].…”

Section: Head and Neck (Handn) Cancersmentioning

confidence: 99%

The Role of Carbon Ion Therapy in the Changing Oncology Landscape—A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological Hadrontherapy

Orlandi,

Barcellini,

Vischioni

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Currently, 13 Asian and European facilities deliver carbon ion radiotherapy (CIRT) for preclinical and clinical activity, and, to date, 55 clinical studies including CIRT for adult and paediatric solid neoplasms have been registered. The National Center for Oncological Hadrontherapy (CNAO) is the only Italian facility able to accelerate both protons and carbon ions for oncological treatment and research. Methods: To summarise and critically evaluate state-of-the-art knowledge on the application of carbon ion radiotherapy in oncological settings, the authors conducted a literature search till December 2022 in the following electronic databases: PubMed, Web of Science, MEDLINE, Google Scholar, and Cochrane. The results of 68 studies are reported using a narrative approach, highlighting CNAO’s clinical activity over the last 10 years of CIRT. Results: The ballistic and radiobiological hallmarks of CIRT make it an effective option in several rare, radioresistant, and difficult-to-treat tumours. CNAO has made a significant contribution to the advancement of knowledge on CIRT delivery in selected tumour types. Conclusions: After an initial ramp-up period, CNAO has progressively honed its clinical, technical, and dosimetric skills. Growing engagement with national and international networks and research groups for complex cancers has led to increasingly targeted patient selection for CIRT and lowered barriers to facility access.

show abstract

Section: Head and Neck (Handn) Cancersmentioning

confidence: 99%